Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Assets AverageEnterprise ValueEquity AverageEquity RatioInterest Coverage RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on EquityTimes Interest Earned

Acro Biomedical (ACBM) Return on Sales (2017 - 2023)

Acro Biomedical has reported Return on Sales over the past 7 years, most recently at 35.34% for Q3 2023.

  • Quarterly results put Return on Sales at 35.34% for Q3 2023, down 2451.0% from a year ago — trailing twelve months through Sep 2023 was 35.34% (down 2451.0% YoY), and the annual figure for FY2022 was 24.1%, down 2275.0%.
  • Return on Sales for Q3 2023 was 35.34% at Acro Biomedical, up from 42.07% in the prior quarter.
  • Over the last five years, Return on Sales for ACBM hit a ceiling of 90.99% in Q3 2019 and a floor of 44.3% in Q1 2023.
  • Median Return on Sales over the past 5 years was 0.6% (2021), compared with a mean of 4.27%.
  • Biggest five-year swings in Return on Sales: skyrocketed 9093bps in 2019 and later plummeted -9114bps in 2020.
  • Acro Biomedical's Return on Sales stood at 0.39% in 2019, then soared by 56bps to 0.17% in 2020, then surged by 2282bps to 3.73% in 2021, then tumbled by -393bps to 10.93% in 2022, then crashed by -223bps to 35.34% in 2023.
  • The last three reported values for Return on Sales were 35.34% (Q3 2023), 42.07% (Q2 2023), and 44.3% (Q1 2023) per Business Quant data.